Posted by Michael Wonder on 11 Sep 2017
A much needed corrective on drug development costs
11 September 2017 - Contemporary pharmaceutical industry pricing practices are threatening to undermine the health care industry’s and policymakers’ efforts at cost control.
Egregious as the price hikes are, the hedge fund managers who gained notoriety for exorbitant price increases on some generics are the least of the problem.
The two biggest drivers of high drug costs in recent years have been the steady increase in prices for existing on-patent drugs, which account for more than 70% of all drug spending, and the 6-figure retail prices set for the latest generation of specialty and cancer therapeutics.
